APA (7th ed.) Citation

Cassier, P., Eberst, L., Garin, G., Courbebaisse, Y., Terret, C., Robert, M., . . . Gomez-Roca, C. (2019). 439O - A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors. Annals of Oncology, 30, v159. https://doi.org/10.1093/annonc/mdz244.001

Chicago Style (17th ed.) Citation

Cassier, P., et al. "439O - A First in Human, Phase I Trial of NP137, a First-in-class Antibody Targeting Netrin-1, in Patients with Advanced Refractory Solid Tumors." Annals of Oncology 30 (2019): v159. https://doi.org/10.1093/annonc/mdz244.001.

MLA (9th ed.) Citation

Cassier, P., et al. "439O - A First in Human, Phase I Trial of NP137, a First-in-class Antibody Targeting Netrin-1, in Patients with Advanced Refractory Solid Tumors." Annals of Oncology, vol. 30, 2019, p. v159, https://doi.org/10.1093/annonc/mdz244.001.